Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
IPO Year: 2014
Exchange: NASDAQ
Website: flexiontherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/19/2021 | Outperform → Market Perform | Northland Capital Markets | |
| 10/19/2021 | $25.00 → $10.00 | Buy → Neutral | HC Wainwright & Co. |
| 10/12/2021 | $20.00 → $12.00 | Outperform → Market Perform | BMO Capital |
| 10/12/2021 | Strong Buy → Market Perform | Raymond James | |
| 10/12/2021 | $14.00 → $10.00 | Outperform → Neutral | Credit Suisse |
| 8/6/2021 | $8.00 → $6.00 | Neutral | Goldman Sachs |
| 8/5/2021 | $20.00 → $18.00 | Buy | Needham |
4 - Flexion Therapeutics Inc (0001419600) (Issuer)
3 - Flexion Therapeutics Inc (0001419600) (Issuer)
4 - Flexion Therapeutics Inc (0001419600) (Issuer)
4 - Flexion Therapeutics Inc (0001419600) (Issuer)
4 - Flexion Therapeutics Inc (0001419600) (Issuer)
4 - Flexion Therapeutics Inc (0001419600) (Issuer)
4 - Flexion Therapeutics Inc (0001419600) (Issuer)
4 - Flexion Therapeutics Inc (0001419600) (Issuer)
4 - Flexion Therapeutics Inc (0001419600) (Issuer)
4 - Flexion Therapeutics Inc (0001419600) (Issuer)
SC 13G/A - Flexion Therapeutics Inc (0001419600) (Subject)
SC 13G/A - Flexion Therapeutics Inc (0001419600) (Subject)
SC 13G/A - Flexion Therapeutics Inc (0001419600) (Subject)
SC 13G/A - Flexion Therapeutics Inc (0001419600) (Subject)
SC 13G/A - Flexion Therapeutics Inc (0001419600) (Subject)
SC 13G - Flexion Therapeutics Inc (0001419600) (Subject)
SC 13G - Flexion Therapeutics Inc (0001419600) (Subject)
Northland Capital Markets downgraded Flexion Therapeutics from Outperform to Market Perform
HC Wainwright & Co. downgraded Flexion Therapeutics from Buy to Neutral and set a new price target of $10.00 from $25.00 previously
BMO Capital downgraded Flexion Therapeutics from Outperform to Market Perform and set a new price target of $12.00 from $20.00 previously
Raymond James downgraded Flexion Therapeutics from Strong Buy to Market Perform
Credit Suisse downgraded Flexion Therapeutics from Outperform to Neutral and set a new price target of $10.00 from $14.00 previously
Goldman Sachs reiterated coverage of Flexion Therapeutics with a rating of Neutral and set a new price target of $6.00 from $8.00 previously
Needham reiterated coverage of Flexion Therapeutics with a rating of Buy and set a new price target of $18.00 from $20.00 previously
Credit Suisse reiterated coverage of Flexion Therapeutics with a rating of Outperform and set a new price target of $14.00 from $17.00 previously
Credit Suisse resumed coverage of Flexion Therapeutics with a rating of Outperform and set a new price target of $17.00
Credit Suisse reiterated coverage of Flexion Therapeutics with a rating of Outperform and set a new price target of $17.00 from $18.00 previously
15-12B - Flexion Therapeutics Inc (0001419600) (Filer)
EFFECT - Flexion Therapeutics Inc (0001419600) (Filer)
S-8 POS - Flexion Therapeutics Inc (0001419600) (Filer)
S-8 POS - Flexion Therapeutics Inc (0001419600) (Filer)
S-8 POS - Flexion Therapeutics Inc (0001419600) (Filer)
S-8 POS - Flexion Therapeutics Inc (0001419600) (Filer)
S-8 POS - Flexion Therapeutics Inc (0001419600) (Filer)
S-8 POS - Flexion Therapeutics Inc (0001419600) (Filer)
S-8 POS - Flexion Therapeutics Inc (0001419600) (Filer)
S-8 POS - Flexion Therapeutics Inc (0001419600) (Filer)
Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced the appointment of Adam Muzikant, PhD, as Chief Business Officer. Dr. Muzikant brings 18 years of business development experience creating and executing value-creating deals, from platform collaborations to commercial-stage product licenses and M&A, across a range of therapeutic areas and technologies at both private and public biopharmaceutical companies. In his role at Avilar, Dr. Muzikant will be responsible for corporate and business development as well as various business operations functions. This press release features multimedia. View the full release here: https://www.busi
-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- TAMPA, Fla. and BURLINGTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the completion of its previously announced acquisition of Flexion Therapeutics, Inc. (NASDAQ:FLXN). "This is an exciting day for Pacira BioSciences as this acquisition expands our industry leadership and marks a major milestone in our strategy to build a robust offering of novel, non-opioid treatments to im
-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- -- Further enhances topline revenue growth; provides attractive potential synergies and expected to be accretive to full-year 2022 earnings and significantly accretive thereafter -- -- Pacira to host conference call today at 8:30 AM ET -- TAMPA, Fla. and BURLINGTON, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, and Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced a definitive agreement
BURLINGTON, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced equity inducement grants to three new employees consisting of 6,315 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of October 1, 2021. The restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units vest over four years, with 25% of the shares vesting on each annual anniversary of the applicable vesting commencement date, subject to the new employee's continued service relat
BURLINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in a virtual analyst-led fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021. The presentation will be available through an on-demand webcast beginning at 7 a.m. ET on September 13, 2021, and will be accessible on the Flexion website at http://ir.flexiontherapeutics.com. About Flexion TherapeuticsFlexion Therapeutics (NASDAQ:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies f
BURLINGTON, Mass., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2021 Virtual Healthcare Conference. The virtual fireside chat is scheduled to begin at 4:35 p.m. ET on Thursday, September 9, 2021. To access the live webcast of the presentation, please visit the Flexion website at http://ir.flexiontherapeutics.com. About Flexion TherapeuticsFlexion Therapeutics (NASDAQ:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with
AAOS finds that ZILRETTA (triamcinolone acetonide extended-release injectable suspension) can improve patient outcomes over immediate-release corticosteroids BURLINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced that the American Academy of Orthopaedic Surgeons (AAOS) included ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in its updated evidence-based clinical practice guidelines for the management of osteoarthritis (OA) of the knee.1 The AAOS guidelines reflect a moderate recommendation for the use of intra-articular (IA) corticosteroids for patients with symptomatic OA of the knee. The recommendation fol
Initial findings from proof-of-concept trial in patients undergoing bunionectomy support expansion of the study to include 36 additional patientsData from the trial, including the expansion cohort, anticipated by year-end BURLINGTON, Mass., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced the expansion of the Phase 1b randomized, double-blind, placebo-controlled trial of FX301 in patients undergoing bunionectomy. FX301 is a novel formulation of a locally administered NaV1.7 inhibitor (funapide) which aims to provide at least three to five days of post-operative pain relief while preserving motor function. The company's decision to advance FX301
Data published in Drugs in R&D confirms extended-release PK profile of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in patients with shoulder OA Plasma PK data indicate the total and maximal exposure to triamcinolone acetonide (TA) was approximately two-thirds lower in patients treated with ZILRETTA compared to triamcinolone acetonide in crystalline suspension (TAcs)Registration trial in patients with shoulder OA expected to begin later this year BURLINGTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced that the results from the randomized, open-label, Phase 2 pharmacokinetic (PK) trial of ZILRETTA (triamcinolone a
ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales were $28.2 million in Q2 2021, reflecting growth of 15% over the previous quarterNet loss in Q2 2021 decreased by $10.4 million (32%), as compared to Q2 2020, during the height of the COVID-19 impact on ZILRETTA salesCompany extends estimated cash runway into 2023 by refinancing term loanFlexion reiterates full-year 2021 ZILRETTA net sales guidance in the range of $120 million to $130 millionData for FX301 bunionectomy study and FX201 single ascending dose/expansion knee osteoarthritis (OA) study anticipated by year-endConference call to be held today at 4:30 pm BURLINGTON, Mass., Aug. 04, 2021 (GLOBE NEW
-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- -- Further enhances topline revenue growth; provides attractive potential synergies and expected to be accretive to full-year 2022 earnings and significantly accretive thereafter -- -- Pacira to host conference call today at 8:30 AM ET -- TAMPA, Fla. and BURLINGTON, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, and Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced a definitive agreement
ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales were $28.2 million in Q2 2021, reflecting growth of 15% over the previous quarterNet loss in Q2 2021 decreased by $10.4 million (32%), as compared to Q2 2020, during the height of the COVID-19 impact on ZILRETTA salesCompany extends estimated cash runway into 2023 by refinancing term loanFlexion reiterates full-year 2021 ZILRETTA net sales guidance in the range of $120 million to $130 millionData for FX301 bunionectomy study and FX201 single ascending dose/expansion knee osteoarthritis (OA) study anticipated by year-endConference call to be held today at 4:30 pm BURLINGTON, Mass., Aug. 04, 2021 (GLOBE NEW
BURLINGTON, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced that it will report its second-quarter 2021 financial results after the close of the U.S. financial markets on Wednesday, August 4, 2021 at 4:30 p.m. ET. A live webcast of the conference call can be accessed through the "Investors" tab on the Flexion Therapeutics website, and a replay will be available online after the call. For those planning to ask a question, the dial-in number for the conference call is 855-770-0022 for domestic participants and 908-982-4677 for international participants, with Conference ID # 3846257. Please dial in at least 15 minutes in advance to ensure
Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced the appointment of Adam Muzikant, PhD, as Chief Business Officer. Dr. Muzikant brings 18 years of business development experience creating and executing value-creating deals, from platform collaborations to commercial-stage product licenses and M&A, across a range of therapeutic areas and technologies at both private and public biopharmaceutical companies. In his role at Avilar, Dr. Muzikant will be responsible for corporate and business development as well as various business operations functions. This press release features multimedia. View the full release here: https://www.busi
BURLINGTON, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced the appointment of Utpal Koppikar, Chief Financial Officer of Atara Biotherapeutics, to its Board of Directors. Mr. Koppikar will serve as the chair of Flexion's audit committee. "I am thrilled to welcome Utpal to Flexion's Board, as his extensive financial experience leading biotechnology companies makes him an outstanding addition to our Board of Directors," said Michael Clayman, MD, President and Chief Executive Officer of Flexion Therapeutics. "In addition to Utpal's anticipated contributions guiding our corporate strategy, I look forward to his stewardship and counsel as chai
BURLINGTON, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that William T. Andrews, M.D., F.A.C.P., will join the company as Chief Medical Officer (CMO), effective July 1, 2021. "Will brings an impressive combination of medical, clinical, regulatory and corporate development skills, complemented by deep commercial experience he gained launching seven products throughout his career,” said Michael Clayman, MD, President and Chief Executive Officer of Flexion Therapeutics. “He will play an integral role in building and strengthening our organization, and we could not be more excited to welcome him to our senior management team.” "I have be